J Gastric Cancer.  2013 Jun;13(2):79-85.

Upper Gastrointestinal Cancer and Reflux Disease

• Kim JJ

Abstract

There is a growing evidence that gastroesophageal reflux disease is related to several upper gastrointestinal cancers, mainly the esophageal adenocarcinoma and a certain type of gastric cardia adenocarcinoma. Currently, the incidence of gastroesophageal reflux disease is rapidly increasing in Korea. Therefore, there is a possibility of such increasing cancerous incidents, similar to the western worlds. In this article, the relationship between gastroesophageal reflux disease and several upper gastrointestinal cancers, the components of refluxate which has possible causal relationship with carcinogenesis, and the clinical implications of such relationship in the management of gastroesophageal reflux disease patients are discussed through the review of literature.

Keyword

Gastroesophageal reflux disease; Gastrointestinal cancer; Fundoplication

MeSH Terms

Adenocarcinoma
Cardia
Fundoplication
Gastroesophageal Reflux
Gastrointestinal Neoplasms
Humans
Incidence
Korea
Western World

Reference

1. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999. 340:825–831.

2. Thrift AP, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol. 2012. 2:11.

3. Lundell LR. Etiology and risk factors for esophageal carcinoma. Dig Dis. 2010. 28:641–644.

4. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut. 2007. 56:918–925.

5. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut. 2008. 57:298–305.

6. Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, et al. Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol. 2011. 46:710–719.

7. Nunobe S, Nakanishi Y, Taniguchi H, Sasako M, Sano T, Kato H, et al. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int. 2007. 57:315–321.

8. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am. 2009. 18:469–485.

9. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G, et al. Barrett's esophagus and esophageal cancer: an overview. Int J Oncol. 2012. 41:414–424.

10. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg. 2011. 15:708–718.

11. Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, et al. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study. J Gastroenterol Hepatol. 2012. 27:741–745.

12. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009. 24:729–735.

13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010. 127:2893–2917.

14. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003. 349:2241–2252.

15. Fujiwara Y, Takahashi S, Arakawa T, Sollano JD, Zhu Q, Kachintorn U, et al. IGICS Study Group. A 2008 questionnaire-based survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries. Digestion. 2009. 80:119–128.

16. Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013. 108:200–207.

17. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study. Am J Gastroenterol. 2006. 101:1193–1199.

18. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995. 274:474–477.

19. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010. 32:1222–1227.

20. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005. 97:1471–1478.

21. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002. 122:26–33.

22. Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O'Rourke RW, et al. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg. 2011. 146:851–858.

23. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004. 20:637–643.

24. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, et al. Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 2010. 139:73–83.

25. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila). 2008. 1:308–311.

26. Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma--a systematic review and meta-analysis. Ann Oncol. 2011. 22:754–760.

27. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008. 1:329–338.

28. 2010 Annual report of the Korea central cancer registry. Accessed May 30, 2013. Available at: http://www.ncc.re.kr/.

29. Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, et al. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer. 1994. 73:2691–2694.

30. Hansson LR, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology. 1995. 109:885–888.

31. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997. 40:297–301.

32. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001. 345:784–789.

33. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009. 125:666–673.

34. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002. 11:235–256.

35. Kim JY, Lee HS, Kim N, Shin CM, Lee SH, Park YS, et al. Prevalence and clinicopathologic characteristics of gastric cardia cancer in South Korea. Helicobacter. 2012. 17:358–368.

36. Lee JY, Kim HY, Kim KH, Jang HJ, Kim JB, Lee JH, et al. No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci. 2003. 18:53–57.

37. Kim JI, Kim SG, Kim N, Kim JG, Shin SJ, Kim SW, et al. Korean College of Helicobacter and Upper Gastrointestinal Research. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol. 2009. 21:787–793.

38. Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol. 2011. 24:1177–1190.

39. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology. 1991. 101:1149–1158.

40. Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther. 2001. 15:269–276.

41. Orlando RC. Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am. 2005. 89:219–241.

42. Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, et al. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci. 2011. 1232:1–17.

43. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg. 1995. 222:525–531.

44. Kauer WK, Stein HJ. Emerging concepts of bile reflux in the constellation of gastroesophageal reflux disease. J Gastrointest Surg. 2010. 14:Suppl 1. S9–S16.

45. Bremner CG, Lynch VP, Ellis FH Jr. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery. 1970. 68:209–216.

46. Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP. Experimental columnar metaplasia in the canine oesophagus. Br J Surg. 1988. 75:113–115.

47. Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology. 1983. 85:621–628.

48. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg. 1996. 224:358–370.

49. Cheng P, Li JS, Gong J, Zhang LF, Chen RZ. Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J Gastroenterol. 2011. 17:3060–3065.

50. Yamada T, Ishida Y, Nakamura Y, Shimada S. Bile-acid-induced calcium signaling in mouse esophageal epithelial cells. Biochem Biophys Res Commun. 2011. 414:789–794.

51. Zhang T, Zhang F, Han Y, Gu Z, Zhou Y, Cheng Q, et al. A rat surgical model of esophageal metaplasia and adenocarcinoma-induced by mixed reflux of gastric acid and duodenal contents. Dig Dis Sci. 2007. 52:3202–3208.

52. Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J Gastrointest Surg. 1998. 2:260–268.

53. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996. 111:1192–1199.

54. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994. 107:747–754.

55. Waring JP, Legrand J, Chinichian A, Sanowski RA. Duodenogastric reflux in patients with Barrett's esophagus. Dig Dis Sci. 1990. 35:759–762.

56. Lirón R, Parrilla P, Martinez de Haro LF, Ortiz A, Robles R, Luján JA, et al. Quantification of duodenogastric reflux in Barrett's esophagus. Am J Gastroenterol. 1997. 92:32–36.

57. Stein HJ, Feussner H, Kauer W, DeMeester TR, Siewert JR. Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg. 1994. 167:163–168.

58. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery. 1997. 122:874–881.

59. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg. 1995. 82:657–660.

60. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg. 1992. 216:35–43.

61. Hopwood D, Bateson MC, Milne G, Bouchier IA. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut. 1981. 22:306–311.

62. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999. 44:598–602.

63. Bajpai M, Aviv H, Das KM. Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Mol Cytogenet. 2012. 5:43.

64. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001. 285:2331–2338.

65. Ye W, Chow WH, Lagergren J, Yin L, Nyrén O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001. 121:1286–1293.

66. DeMeester SR. Antireflux surgery and the risk of esophageal adenocarcinoma: an antithetical view of the data from sweden. Ann Surg. 2013. 257:583–585.

67. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg. 2003. 238:458–464.

68. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, De-Meester SR, Crookes PF, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg. 2001. 234:532–538.

69. Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol. 2006. 101:1458–1466.

70. Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg. 2007. 142:554–559.

71. Martinez de Haro LF, Ortiz A, Parrilla P, Munitiz V, Martinez CM, Revilla B, et al. Long-term follow-up of malignancy biomarkers in patients with Barrett's esophagus undergoing medical or surgical treatment. Ann Surg. 2012. 255:916–921.

72. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001. 120:1599–1606.

73. Tamhankar AP, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg. 2004. 8:890–897.

74. Gutschow CA, Bludau M, Vallböhmer D, Schröder W, Bollschweiler E, Hölscher AH. NERD, GERD, and Barrett's esophagus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring. Dig Dis Sci. 2008. 53:3076–3081.

75. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg. 1998. 2:333–341.

76. Lee SK, Kim EK. Laparoscopic Nissen fundoplication in Korean patients with gastroesophageal reflux disease. Yonsei Med J. 2009. 50:89–94.